Dabrafenib and trametinib, inhibiting BRAF and MEK proteins, respectively (Figure 2), have shown durable responses and manageable toxicity in treating not only melanoma but also other BRAF-positive solid tumours, such as NSCLC, anaplastic thyroid cancer (ATC), and various other cancers [99,100,101]. Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.